Answers are grounded in this paper and cite their sources.
Ineffective erythropoiesis, the intramedullary death of maturing erythroid precursors, underlies the anemia of β-thalassemia and myelodysplastic syndrome (MDS), two disorders whose treatment goals diverge sharply: rescuing failing precursors in one, eliminating a dysplastic clone in the other. Ferroptosis, an iron-dependent regulated cell death driven by lipid peroxidation, is a mechanistic node that could in principle be pushed either way. Literature search: PubMed/MEDLINE, Scopus and Web of Science Core Collection, with Consensus as a supplementary semantic search, searched from 1990 to 2026. This review synthesizes the iron and lipid-peroxidation biology underlying erythroid ferroptosis susceptibility and finds the evidence markedly uneven: MDS has direct, patient-derived ferroptosis-marker data, while β-thalassemia rests on correlative murine and transcriptomic evidence, with no human functional data; disorders such as pyruvate kinase deficiency have none. Red cell-inspired nanocarriers, including membrane-coated, deformability-mimicking, and hemoglobin-based platforms, are evaluated as a delivery strategy, given their native spleen tropism and, with added ligands, bone marrow targeting. Component technologies, including membrane cloaking, ferroptosis-modulator encapsulation, marrow-homing ligands, and biodistribution imaging, are each mature, yet no study integrates them into a single validated platform. We propose screening under-studied iron-loading anemias for ferroptosis markers and pairing carrier imaging with pharmacodynamic biomarkers in early-phase studies.
No takes yet. Share an insight, caveat, or question.
Parameswaran et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: